Global Thyroid Gland Disorder Treatment Market Growth, Size, Trends Analysis - By Indication, By Drug, By Distribution Channel, By Route of Administration - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

Thyroid Gland Disorder Treatment Market Introduction and Overview

According to SPER market research, 'Global Thyroid Gland Disorder Treatment Market Size- By Indication, By Drug, By Distribution Channel, By Route of Administration - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Thyroid Gland Disorder Treatment Market is predicted to reach 3.37 billion by 2034 with a CAGR of 3.85%.

Thyroid gland disease treatment includes medical procedures and therapies designed to manage thyroid gland conditions. The thyroid gland, located in the front of the neck, regulates several biological activities by producing thyroid hormones, most notably thyroxine (T4) and triiodothyronine (T3). Thyroid problems, which include hypothyroidism, hyperthyroidism, Graves' disease, thyroid nodules, thyroiditis, and thyroid cancer, are on the rise globally due to a variety of causes such as aging populations, environmental impacts, and lifestyle changes.

Restraints: Limited access to healthcare services is a major challenge for treating thyroid gland disorders worldwide, especially in low- and middle-income countries. Many people with thyroid issues like hypothyroidism, hyperthyroidism, and thyroid nodules find it hard to get timely diagnosis and treatment due to poor healthcare facilities.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Indication, By Drug, By Distribution Channel, By Route of Administration

Regions covered North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered Abbvie Inc, Amgen Inc, GSK Plc, Merck KGaA, Viatris Inc, Novartis AG, Pfizer Inc, Takeda Pharmaceutical Company Limited, Elexis Inc, IBSA Pharma (IBSA Group).

Global Thyroid Gland Disorder Treatment Market Segmentation:

By Indication: Based on the Indication, Global Thyroid Gland Disorder Treatment Market is segmented as; Hypothyroidism, Hyperthyroidism.

By Drug: Based on the Drug, Global Thyroid Gland Disorder Treatment Market is segmented as; Levothyroxine, Liothyronine, Propylthiouracil, Imidazole-based compounds, Others.

By Distribution Channel: Based on the Distribution Channel, Global Thyroid Gland Disorder Treatment Market is segmented as; Wholesale Distribution, Retail Stores, Online Pharmacy.

By Route of Administration: Based on the Route of Administration, Global Thyroid Gland Disorder Treatment Market is segmented as; Oral, Intravenous, Others.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Product Code: HLCA25126

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1.Secondary Data
- 2.1.2.Primary Data
- 2.1.3.SPER's internal database
- 2.1.4.Premium insight from KOL's
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1.Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1.Drivers
- 4.1.2.Restraints
- 4.1.3.Opportunities
- 4.1.4.Challenges

5. Market variable and outlook

5.1.SWOT Analysis
- 5.1.1.Strengths
- 5.1.2.Weaknesses
- 5.1.3.Opportunities
- 5.1.4.Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTER's Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1.Global Thyroid Gland Disorder Treatment Market Manufacturing Base Distribution, Sales Area, Product Type
6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Thyroid Gland Disorder Treatment Market

7. Global Thyroid Gland Disorder Treatment Market, By Indication (USD Million) 2021-2034

7.1. Hypothyroidism
7.2. Hyperthyroidism

8. Global Thyroid Gland Disorder Treatment Market, By Drug (USD Million) 2021-2034

8.1. Levothyroxine
8.2. Liothyronine
8.3. Propylthiouracil
8.4. Imidazole-based compounds
8.5. Others

9. Global Thyroid Gland Disorder Treatment Market, By Distribution Channel (USD Million) 2021-2034

9.1. Wholesale Distribution
9.2. Retail Stores
9.3. Online Pharmacy

10. Global Thyroid Gland Disorder Treatment Market, By Route of Administration (USD Million) 2021-2034

10.1.Oral
10.2.Intravenous
10.3.Others

11. Global Thyroid Gland Disorder Treatment Market, (USD Million) 2021-2034

11.1. Global Thyroid Gland Disorder Treatment Market Size and Market Share

12. Global Thyroid Gland Disorder Treatment Market, By Region, (USD Million) 2021-2034

12.1. Asia-Pacific
- 12.1.1. Australia
- 12.1.2. China
- 12.1.3. India
- 12.1.4. Japan
- 12.1.5. South Korea
- 12.1.6. Rest of Asia-Pacific
12.2. Europe
- 12.2.1. France
- 12.2.2. Germany
- 12.2.3. Italy
- 12.2.4. Spain
- 12.2.5. United Kingdom
- 12.2.6. Rest of Europe
12.3. Middle East and Africa
- 12.3.1. Kingdom of Saudi Arabia
- 12.3.2. United Arab Emirates
- 12.3.3. Qatar
- 12.3.4. South Africa
- 12.3.5. Egypt
- 12.3.6. Morocco
- 12.3.7. Nigeria
- 12.3.8. Rest of Middle-East and Africa
12.4.North America
- 12.4.1.Canada
- 12.4.2.Mexico
- 12.4.3.United States
12.5.Latin America
- 12.5.1.Argentina
- 12.5.2.Brazil
- 12.5.3.Rest of Latin America

13. Company Profile

13.1. Abbvie Inc
- 13.1.1. Company details
- 13.1.2. Financial outlook
- 13.1.3. Product summary
- 13.1.4. Recent developments
13.2. Amgen Inc
- 13.2.1. Company details
- 13.2.2. Financial outlook
- 13.2.3. Product summary
- 13.2.4. Recent developments
13.3. GSK Plc
- 13.3.1. Company details
- 13.3.2. Financial outlook
- 13.3.3. Product summary
- 13.3.4. Recent developments
13.4. Merck KGaA
- 13.4.1. Company details
- 13.4.2. Financial outlook
- 13.4.3. Product summary
- 13.4.4. Recent developments
13.5.Viatris Inc
- 13.5.1. Company details
- 13.5.2. Financial outlook
- 13.5.3. Product summary
- 13.5.4. Recent developments
13.6. Novartis AG
- 13.6.1. Company details
- 13.6.2. Financial outlook
- 13.6.3. Product summary
- 13.6.4. Recent developments
13.7.Pfizer Inc
- 13.7.1. Company details
- 13.7.2. Financial outlook
- 13.7.3. Product summary
- 13.7.4. Recent developments
13.8. Takeda Pharmaceutical Company Limited
- 13.8.1. Company details
- 13.8.2. Financial outlook
- 13.8.3. Product summary
- 13.8.4. Recent developments
13.9. Elexis Inc
- 13.9.1. Company details
- 13.9.2. Financial outlook
- 13.9.3. Product summary
- 13.9.4. Recent developments
13.10. IBSA Pharma (IBSA Group)
- 13.10.1. Company details
- 13.10.2. Financial outlook
- 13.10.3. Product summary
- 13.10.4. Recent developments
13.11. Others